Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group

Blood

Volumn 93, Issue 12, 1999, Pages 4116-4124

  Büchner, Thomas ^a   Hiddemann, Wolfgang ^b   Wörmann, Bernhard ^b   Löffler, Helmut ^b   Gassmann, Winfried ^b   Haferlach, Torsten ^b   Fonatsch, Christa ^b   Haase, Detlef ^b   Schoch, Claudia ^b   Hossfeld, Dieter ^b   Lengfelder, Eva ^b   Aul, Carlo ^b   Heyll, Axel ^b   Maschmeyer, Georg ^b   Ludwig, Wolf Dieter ^b   Sauerland, Maria Cristina ^b   Heinecke, Achim ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CYTARABINE; DAUNORUBICIN; HUMANS; KARYOTYPING; L-LACTATE DEHYDROGENASE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MIDDLE AGED; MITOXANTRONE; PROGNOSIS; REMISSION INDUCTION; THIOGUANINE; TREATMENT OUTCOME;

EID: 0345104178     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK: Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B. Blood 58:1203, 1981
2. Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, Nowrousian MR, König HJ, Walter M, Wendt FC, Sodomann H, Hossfeld DK, von Paleske A, Löffler H, Gassmann W, Hellriegel KP, Fülle HH, Lunscken C, Emmerich B, Pralle H, Bonfert B, Köppler H, Zurborn KH, Ranft K, Thiel E, Heinecke A: Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3:1583, 1985
3. th acute leukemia trial. Lancet 29:1236, 1986
4. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O'Connel MJ: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79:1924, 1992
5. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulmann P, Omura GA, Moore JO, McIntyre OR, Frei E: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896, 1994
6. Zittoun RA, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217, 1995
7. Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB, Killmann SA, Jensen MK, Laursen KH, Nielsen JB, Nissen NI, Thorling K: Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: A Danish national phase III trial. Leukemia 5:510, 1991
8. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710, 1996
9. Burnett AK, Goldstone AH, Stevens RMF, Hann IM, Rees JKH, Gray RG, Wheatly K, for the UK Medical Research Council Adult and Children's Leukaemia Working Parties: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. Lancet 351:700, 1998
10. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers, JN, Hynes HE, Welborn JL, Simon SR, Grever M: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood 88:2841, 1996
11. Bloomfield CD, Lawrence D, Byrd JC, Caroll A, Pettaniti MJ, Trantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173, 1998
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the acute leukemias. Br J Haematol 33:451, 1976
13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:626, 1985
14. Büchner T, Urbanitz D, Emmerich B, Fischer JT, Fülle HH, Heinecke A, Hossfeld DK, Koeppen KM, Labedzki L, Löffler H, Nowrousian MR, Pfreundschuh M, Pralle H, Rühl H, Wendt FC: Multicenter study on intensified remission induction therapy for acute myeloid leukemia. Leuk Res 6:827, 1982
15. Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T: High-dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia. Blood 69:744, 1987
16. Mitelmann F (ed): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1995
17. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
18. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson U, Peto J, Smith PG: Design and analysis of randomized clinical trials requiering prolonged observation of each patient. D. Analysis and example. Br J Cancer 35:1, 1977
19. Cox DR: Regression models and live tables (with discussion) J R Stat Soc B 34:187, 1972
20. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322, 1998
21. th AML Trial (MRC AML10). Blood 89:2311, 1997
22. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willmann C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339:1649, 1998
23. Willemze R, Zwaan FE, Coplin G, Keuning JJ: High-dose cytosine arabinoside in the management of refractory acute leukemia. Scand J Haematol 29:141, 1982
24. Herzig RH, Wolff SN, Lazarus HM, Phillips GS, Karanes C, Herzig GP: High-dose cytosine arabinoside therapy for refractory leukemia. Blood 52:361, 1983
25. Capizzi RL, Poole M, Cooper MR, Richards FII, Stuart JJ, Jackson DV Jr, White DR, Spurr CI, Hopkins JO, Muss HB, Rudick SA, Wells R, Gabriel D, Ross D: Treatment of poor risk acute leukemia with sequential high-dose AraC and asparaginase. Blood 63:694, 1984
26. Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick JH: High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J Clin Oncol 2:545, 1984
27. Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP: High-dose cytosine arabinoside therapy with and without anthracyline antibiotics for remission re-induction of acute nonlymphoblastic leukemia. J Clin Oncol 3:992, 1985
28. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich FJ: Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 67:389, 1983
29. Arlin ZA, Dukart G, Schoch I, Reismann A, Moore J, Silver RA, Cassileth P, Bertino J, Gams R, the Lederle Cooperative Group: Phase I-II trial of mitoxantrone in acute leukemia. An interim report. J Invest New Drugs 3:213, 1985
30. Meyer P, Ho AD, Ehninger G, Mjasland I, Heidemann E, Seither E: Mitoxantrone in the treatment of relapsed and refractory acute leukemia. J Invest New Drugs 3:203, 1985
31. Büchner T, Barlogie B, Asseburg U, Hiddemann W, Kamanabroo D, Göhde W: Accumulation of S-phase cells in the bone marrow of patients with acute leukemia by cytosine arabinoside. Blut 28:299, 1974
32. Plunkett W, Jacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ: Pharmacologically directed AraC therapy for refractory leukemia. Semin Oncol 12:20, 1985 (suppl 3)
33. Rustum YM, Riva C, Preisler HD: Pharmacokinetic parameters of 1-β-arabinofuranosylcytosine (AraC) and their relationship to intracellular metabolism of AraC, toxicity, and response of patients with conventional and high-dose AraC. Semin Oncol 14:141, 1987 (suppl 1)
34. Capizzi RL, Yang JI, Rathmell JP, White JC, Cheng E, Cheng Y-C, Kute T: Dose-related pharmacologic effects of high-dose AraC and its self-potendation. Semin Oncol 12:65, 1985 (suppl 3)
35. Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Spitzer G, Hersh E, Gutterman J, Freireich EJ: Factors related to length of complete remission in adult acute leukemia. Cancer 45:2017, 1980
36. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987, 1993